Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients
Determining the optimal dose of warfarin for frail elderly patients is a challenging task because of the low dose requirements in such patients, the wide interindividual variability of response, and the associated risk of bleeding. The objective of this study was to address the influence of 13 commo...
Saved in:
Published in | Clinical pharmacology and therapeutics Vol. 87; no. 1; p. 57 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.01.2010
|
Subjects | |
Online Access | Get more information |
ISSN | 1532-6535 |
DOI | 10.1038/clpt.2009.178 |
Cover
Loading…
Abstract | Determining the optimal dose of warfarin for frail elderly patients is a challenging task because of the low dose requirements in such patients, the wide interindividual variability of response, and the associated risk of bleeding. The objective of this study was to address the influence of 13 common variations in eight genes on the maintenance dose of warfarin in a cohort of frail elderly inpatients. For our study, we enrolled 300 Caucasian subjects who were hospital inpatients, with a mean age of 86.7 +/- 6 years. In addition to age, genetic variants of VKORC1, CYP2C9, CYP4F2, and EPHX1 were found to be significant predictor variables for the maintenance dose of warfarin, explaining 26.6% of dose variability. Among 132 patients in whom warfarin therapy was initiated with the same low-dose regimen, we studied the relative influences of genetic and nongenetic factors. The time to first international normalized ratio (INR) > or =2 was influenced by VKORC1 and CYP2C9 genotypes (P = 0.0003 and P = 0.0016, respectively); individuals with multiple variant alleles were at highest risk for overanticoagulation (INR >4) (odds ratio, 12.8; 95% confidence interval, 2.73-60.0). In this special population of frail elderly patients with multiple comorbidities and polypharmacy, we demonstrated the main impact of genetic factors on warfarin response. |
---|---|
AbstractList | Determining the optimal dose of warfarin for frail elderly patients is a challenging task because of the low dose requirements in such patients, the wide interindividual variability of response, and the associated risk of bleeding. The objective of this study was to address the influence of 13 common variations in eight genes on the maintenance dose of warfarin in a cohort of frail elderly inpatients. For our study, we enrolled 300 Caucasian subjects who were hospital inpatients, with a mean age of 86.7 +/- 6 years. In addition to age, genetic variants of VKORC1, CYP2C9, CYP4F2, and EPHX1 were found to be significant predictor variables for the maintenance dose of warfarin, explaining 26.6% of dose variability. Among 132 patients in whom warfarin therapy was initiated with the same low-dose regimen, we studied the relative influences of genetic and nongenetic factors. The time to first international normalized ratio (INR) > or =2 was influenced by VKORC1 and CYP2C9 genotypes (P = 0.0003 and P = 0.0016, respectively); individuals with multiple variant alleles were at highest risk for overanticoagulation (INR >4) (odds ratio, 12.8; 95% confidence interval, 2.73-60.0). In this special population of frail elderly patients with multiple comorbidities and polypharmacy, we demonstrated the main impact of genetic factors on warfarin response. |
Author | Gouin-Thibault, I Durand-Gasselin, B Moreau, C Taillandier-Hériche, E Pautas, E Siguret, V Mahé, I Legendre, C Golmard, J-L Houllier, A-M Beaune, P Verrier, P Loriot, M-A |
Author_xml | – sequence: 1 givenname: E surname: Pautas fullname: Pautas, E organization: Université Paris Descartes, Paris, France – sequence: 2 givenname: C surname: Moreau fullname: Moreau, C – sequence: 3 givenname: I surname: Gouin-Thibault fullname: Gouin-Thibault, I – sequence: 4 givenname: J-L surname: Golmard fullname: Golmard, J-L – sequence: 5 givenname: I surname: Mahé fullname: Mahé, I – sequence: 6 givenname: C surname: Legendre fullname: Legendre, C – sequence: 7 givenname: E surname: Taillandier-Hériche fullname: Taillandier-Hériche, E – sequence: 8 givenname: B surname: Durand-Gasselin fullname: Durand-Gasselin, B – sequence: 9 givenname: A-M surname: Houllier fullname: Houllier, A-M – sequence: 10 givenname: P surname: Verrier fullname: Verrier, P – sequence: 11 givenname: P surname: Beaune fullname: Beaune, P – sequence: 12 givenname: M-A surname: Loriot fullname: Loriot, M-A – sequence: 13 givenname: V surname: Siguret fullname: Siguret, V |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19794411$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kEtLAzEUhYMo9qFLt5KlQqfmNU2ylKEPsdAiRXRVMskNjEynQzJWuvaPm6Kuzj0fnAvnDNB5s28AoRtKxpRw9WDrthszQvSYSnWG-jTnLJvkPO-hQYwfhBChlbpEPaqlFoLSPvqeQwNdZbE3ttuHiO9en1cvBR3h4n3NCj3C0_XiLVnTuBMSM3aPTQDcBnDVKYIPJlSmrCFin9yXCT6BBgeI7b6JgNN9gHDEUDsI9XGEfTBVnXBrugqaLl6hC2_qCNd_OkSb2XRTLLLlav5UPC4zKzhXmZcCnJTWEKkcZUAk584SaonXRhFVeqlyzVPdiTClAuUnKcKVcKAFI2yIbn_ftp_lDty2DdXOhOP2fwz2A6hdX1E |
CitedBy_id | crossref_primary_10_1177_1076029616654264 crossref_primary_10_2217_pgs_2020_0054 crossref_primary_10_1016_j_etap_2015_05_008 crossref_primary_10_1007_s40262_023_01258_y crossref_primary_10_1186_s40246_018_0157_3 crossref_primary_10_1016_S1734_1140_13_70977_0 crossref_primary_10_1007_s00228_018_2528_z crossref_primary_10_2217_pgs_10_49 crossref_primary_10_1016_j_jacc_2010_08_643 crossref_primary_10_2217_pgs_11_156 crossref_primary_10_1016_j_thromres_2011_11_043 crossref_primary_10_1007_s40291_013_0055_2 crossref_primary_10_1517_13543784_2012_707194 crossref_primary_10_1007_s11096_010_9448_z crossref_primary_10_1007_s40266_024_01117_w crossref_primary_10_1093_eurheartj_ehr239 crossref_primary_10_1007_s00228_013_1581_x crossref_primary_10_3389_fphar_2017_00323 crossref_primary_10_1111_j_1365_2125_2010_03709_x crossref_primary_10_2165_10061610_000000000_00000 crossref_primary_10_1007_s11239_012_0725_7 crossref_primary_10_1186_1749_8090_7_97 crossref_primary_10_1586_17512433_2013_842125 crossref_primary_10_1592_phco_31_12_1192 crossref_primary_10_1007_s00228_017_2265_8 crossref_primary_10_1161_CIRCULATIONAHA_109_914820 crossref_primary_10_2217_pgs_11_164 crossref_primary_10_1038_s41397_021_00224_w crossref_primary_10_1038_jhg_2010_73 crossref_primary_10_1016_j_clinbiochem_2012_01_002 crossref_primary_10_1309_AJCPAO82OTNPUBLW crossref_primary_10_1111_j_1365_2710_2011_01317_x crossref_primary_10_1007_s00228_012_1356_9 crossref_primary_10_2217_pgs_2019_0139 crossref_primary_10_2217_pgs_10_162 crossref_primary_10_2217_pgs_12_65 crossref_primary_10_1160_TH13_07_0555 crossref_primary_10_1155_2015_564149 crossref_primary_10_1007_s00204_013_1013_9 crossref_primary_10_1097_FPC_0000000000000244 crossref_primary_10_1182_blood_2011_07_365502 crossref_primary_10_1007_s11096_011_9486_1 crossref_primary_10_3389_fphar_2023_1105702 crossref_primary_10_1016_j_genrep_2020_100769 crossref_primary_10_3389_fphar_2020_01014 crossref_primary_10_1016_j_thromres_2018_05_002 crossref_primary_10_1002_pbc_24932 crossref_primary_10_1016_j_clinthera_2012_02_009 crossref_primary_10_1038_clpt_2011_179 crossref_primary_10_3390_jpm10030117 crossref_primary_10_1002_cpt_1323 crossref_primary_10_1371_journal_pone_0105250 crossref_primary_10_1002_phar_1717 crossref_primary_10_1007_s11834_010_0011_Y crossref_primary_10_1093_hmg_ddq389 crossref_primary_10_1111_j_1365_2710_2012_01340_x crossref_primary_10_1016_S2211_9698_11_71437_6 crossref_primary_10_2217_pgs_12_171 crossref_primary_10_1111_j_1365_2125_2012_04354_x crossref_primary_10_1016_j_jamda_2010_12_006 crossref_primary_10_1016_j_pharep_2013_09_006 crossref_primary_10_2217_fca_10_6 crossref_primary_10_1080_21551197_2012_729902 crossref_primary_10_1038_clpt_2012_184 crossref_primary_10_1111_jth_12105 crossref_primary_10_3390_ph3123543 crossref_primary_10_4155_fsoa_2017_0112 crossref_primary_10_1093_labmed_lmx072 crossref_primary_10_1111_j_1365_2125_2011_04095_x crossref_primary_10_1007_s00228_012_1448_6 crossref_primary_10_1097_HCO_0b013e32835f0bbc crossref_primary_10_1097_FTD_0b013e318256a77c crossref_primary_10_1111_j_1365_2125_2011_03942_x crossref_primary_10_1111_jphp_12084 crossref_primary_10_1016_j_revmed_2009_07_014 crossref_primary_10_1007_s43440_023_00476_2 crossref_primary_10_2217_pme_14_80 crossref_primary_10_1038_clpt_2011_31 crossref_primary_10_1038_clpt_2011_76 crossref_primary_10_1111_j_1538_7836_2011_04213_x crossref_primary_10_2217_pgs_2018_0146 crossref_primary_10_2217_pgs_2018_0143 crossref_primary_10_1038_clpt_2009_307 crossref_primary_10_1007_s00228_010_0950_y crossref_primary_10_1007_s40266_013_0101_0 crossref_primary_10_1016_j_cca_2010_04_014 crossref_primary_10_1016_j_gene_2017_10_049 crossref_primary_10_1016_j_thromres_2013_03_019 crossref_primary_10_1007_s40256_015_0126_3 crossref_primary_10_1007_BF03319099 crossref_primary_10_1007_s11033_014_3617_4 crossref_primary_10_1185_03007995_2014_912982 crossref_primary_10_1097_MD_0000000000005658 crossref_primary_10_1109_JBHI_2014_2336974 crossref_primary_10_1111_bcpt_12024 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1038/clpt.2009.178 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1532-6535 |
ExternalDocumentID | 19794411 |
Genre | Journal Article Comparative Study |
GroupedDBID | --- --K -Q- .55 .GJ 0R~ 1B1 1CY 1OB 1OC 29B 33P 354 36B 39C 3O- 4.4 52O 53G 5GY 5RE 6J9 70F 8F7 AAESR AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AAQOH AAQQT AAWTL AAYCA AAYOK AAZKR ABCUV ABJNI ABLJU ABQWH ACBNA ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACPOU ACRPL ACXQS ACYXJ ADBBV ADBTR ADKYN ADNMO ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AENEX AEQDE AEUYR AFBPY AFFNX AFFPM AGHNM AHBTC AI. AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMYDB ASPBG AVWKF AZFZN AZVAB BDRZF BFHJK BMXJE BRXPI C45 CAG CGR COF CS3 CUY CVF DCZOG DPXWK DU5 EBS ECM EE. EIF EJD EMOBN F5P GODZA GWYGA HGLYW IH2 IHE J5H L7B LATKE LEEKS LITHE LOXES LSO LUTES LYRES M41 MEWTI N4W N9A NPM NQ- O9- OPC OVD P2P P2W PALCI RIG RIWAO RJQFR RNTTT ROL RPZ SAMSI SEW SJN SUPJJ TEORI TWZ UHS VH1 WBKPD WH7 WOHZO WXSBR X7M Y6R YCJ YFH YOC YXB ZGI ZXP ZZTAW |
ID | FETCH-LOGICAL-c4338-f74ed77ca078d12e0733dc01c0f9a808bf7859353564ab8e8f6f74384de94202 |
IngestDate | Thu Apr 03 07:05:46 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4338-f74ed77ca078d12e0733dc01c0f9a808bf7859353564ab8e8f6f74384de94202 |
PMID | 19794411 |
ParticipantIDs | pubmed_primary_19794411 |
PublicationCentury | 2000 |
PublicationDate | January 2010 |
PublicationDateYYYYMMDD | 2010-01-01 |
PublicationDate_xml | – month: 01 year: 2010 text: January 2010 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Clinical pharmacology and therapeutics |
PublicationTitleAlternate | Clin Pharmacol Ther |
PublicationYear | 2010 |
References | 21593757 - Clin Pharmacol Ther. 2011 Jun;89(6):791; author reply 792 |
References_xml | – reference: 21593757 - Clin Pharmacol Ther. 2011 Jun;89(6):791; author reply 792 |
SSID | ssj0004988 |
Score | 2.3406677 |
Snippet | Determining the optimal dose of warfarin for frail elderly patients is a challenging task because of the low dose requirements in such patients, the wide... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 57 |
SubjectTerms | Age Factors Aged Aged, 80 and over Aryl Hydrocarbon Hydroxylases - genetics Cohort Studies Cytochrome P-450 CYP2C9 Cytochrome P-450 Enzyme System - genetics Cytochrome P450 Family 4 Dose-Response Relationship, Drug Epoxide Hydrolases - genetics Female Frail Elderly Genetic Testing Genetic Variation - drug effects Genetic Variation - genetics Hospitalization - trends Humans International Normalized Ratio - trends Male Mixed Function Oxygenases - genetics Polymorphism, Genetic - genetics Prospective Studies Risk Factors Vitamin K Epoxide Reductases Warfarin - pharmacology |
Title | Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients |
URI | https://www.ncbi.nlm.nih.gov/pubmed/19794411 |
Volume | 87 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELa6cOGCeD8W0BzQCtQEktR5-IgqdquFhQgFVE4rJ7FFpW4bdVtQufKb-H_M2HGbLg8BlyhyFCvy92k8nsx8w9jjStWDMFGBr3gW-FzFaAdrFfvkXAiZCRkKKk4-eZOM3vPjcTzu9b53spZWy_JZ9fWXdSX_gyqOIa5UJfsPyG4mxQG8R3zxigjj9a8wJs1oElx1TXPQW_zw6u27YWjCnx_zaCiMrctH49ClaeIwP4woGEA5X82CftTgy_3PeGimMiqjz9D_IhcaB6jWxeTQGmkRXJ91X1Fbb9ueWi_khCQ7Wm3W866jO3QVl81WG3vt0jVdxdfGn88lpYbvFEaczNGdXe3EcY_mq8nMLz5NSrmaLndCvkfz6Zm0WfrH_utuKMNkxLlQhnLmN_KT2AqYOPvcbshdHlpja5Wtf9oDrOJ7NW2WVo40tD2COnxozgwhQoHGiFtb_-enFyS53aM9toeHE-q2SiEiV4wrsqwVc8Uveb7zHUai1r574Rhj3JniGrvankPghSXVddZTsxvsILdgrT0oOih5cAB5B8ab7FvLPGiZB08s7zywrPPAcM4DBBws454C8g02fIMN3wD5Bo5v4PgGeE98g5ZvHhi2wZZtt1hx-LIYjvy2nYdf8QFuqzrlqk7TSqJXWoeRonahdRWEVaDRKgRZqVMS30P0Ey7LTGU6wVcGGa-V4FEQ3WaXZvOZussAjzg6LXGWIKt4IkUZ64Dm1QLdXxlE99gdu7anjZVsOXWrfv-3T_bZlS0lH7DLGm2EeogO57J8ZAD-AdD9fY8 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genetic+factors+%28VKORC1%2C+CYP2C9%2C+EPHX1%2C+and+CYP4F2%29+are+predictor+variables+for+warfarin+response+in+very+elderly%2C+frail+inpatients&rft.jtitle=Clinical+pharmacology+and+therapeutics&rft.au=Pautas%2C+E&rft.au=Moreau%2C+C&rft.au=Gouin-Thibault%2C+I&rft.au=Golmard%2C+J-L&rft.date=2010-01-01&rft.eissn=1532-6535&rft.volume=87&rft.issue=1&rft.spage=57&rft_id=info:doi/10.1038%2Fclpt.2009.178&rft_id=info%3Apmid%2F19794411&rft_id=info%3Apmid%2F19794411&rft.externalDocID=19794411 |